AlloVir, Inc. (ALVR)

Market Cap	49.21M
Revenue (ttm)	n/a
Net Income (ttm)	-58.77M
Shares Out	5.02M
EPS (ttm)	-11.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,402
Open	9.55
Previous Close	9.42
Day's Range	9.55 - 10.32
52-Week Range	7.96 - 24.15
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2025

About ALVR

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenz...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2020
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: ALVR
• Website: https://www.allovir.com